Anti-Mi-2 antibodies.
Autoantibodies targeting the Mi-2 nuclear antigen represent one of the serologic hallmarks of idiopathic inflammatory myopathies, with a diagnostic sensitivity and specificity of approximately 4-18% and 98-100%, respectively. Mi-2 antigen is a component of the nuclesome remodeling-deacetylase (NuRD) complex involved in transcription regulation.Anti-Mi-2 antibodies are strongly associated with dermatomyositis (frequency up to 31%) and have a very high positive predictive value for such disease subset. A strong correlation with HLA-DR7 has been demonstrated. At the moment, optimal serologic testing is achieved by ELISA screening on recombinant Mi-2 antigen and confirmation of positive results on immunoblot.
Ghirardello
Anna
A
Division of Rheumatology, Medical Clinics, Department of Medical and Surgical Sciences, University of Padova, Italy.
Zampieri
Sandra
S
Iaccarino
Luca
L
Tarricone
Elena
E
Bendo
Raffaele
R
Gambari
Pier Franca
PF
Doria
Andrea
A
D001323:Autoantibodies / Q000097:blood* / Q000266:history; D003882:Dermatomyositis / Q000175:diagnosis / Q000276:immunology; D003937:Diagnosis, Differential; D019084:Fluorescent Antibody Technique, Indirect / Q000379:methods / Q000706:statistics & numerical data; D049673:History, 20th Century; D006801:Humans; D007132:Immunoglobulin Isotypes / Q000097:blood; D009220:Myositis / Q000175:diagnosis / Q000276:immunology; D017285:Polymyositis / Q000175:diagnosis / Q000276:immunology; D012680:Sensitivity and Specificity
D001323:Autoantibodies; D007132:Immunoglobulin Isotypes; C045760:Mi-2 antibodies